Why BioMarin FDA Panel is Positive for Sarepta (SRPT) - Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Needham & Company Remains Confident in Sarepta Therapeutic (SRPT) Approval
November 25, 2015 12:09 PM ESTNeedham & Company analyst Chad Messer reiterated a Buy rating and $55 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying they remain confident in Eteplirsen approval following Drisapersen's AdCom.
Messer commented, "As expected, most of the discussion yesterday was around inconsistencies in the drisapersen... More
Sarepta (SRPT) PT Raised at Jefferies as BioMarin AdCom Viewed as a Positive But Remains Cautious
November 25, 2015 7:27 AM ESTJefferies analyst Gena Wang views the negative AdCom outcome for BMRN's drisapersen as a positive for Sarepta Therapeutic (NASDAQ: SRPT), although questions remain. As such the firm raised its price target to $38.00 (from $28.00) but maintained a Hold rating.
Wang commented, "We view negative... More
Sarepta Therapeutics (SRPT) on Watch as BioMarin's (BMRN) Kyndrisa Adcom Set to Kickoff
November 24, 2015 7:46 AM ESTSarepta Therapeutics (NASDAQ: SRPT) was on watch Tuesday morning ahead of competitor BioMarin's (Nasdaq: BMRN) Kyndrisa FDA committee review. The advisory meeting runs from 8:00 a.m. to 5:30 p.m. EST.
... MoreFDA Briefing Docs Offer Positives and Negatives for Sarepta (SRPT) - Baird
November 23, 2015 6:55 AM ESTBaird analyst, Brian Skorney, published a note this morning highlighting his interpretation of the FDA Briefing Documents on BioMarin's (NASDAQ: BMRN) drisapersen filed Friday. He still believes that Sarepta (NASDAQ: SRPT) has only a 35% chance of getting approval for eteplirsen... More
